嵌合抗原受体修饰的NK细胞免疫治疗在血液肿瘤中的研究进展

Progress of chimeric antigen receptor modified natural killer cells immunotherapy in hematological neoplasms

嵌合抗原受体T细胞（CAR—T）是近年发展起来的免疫治疗新方法，通过T细胞的基因修饰，使其特异性识别靶抗原，产生特异性的杀伤作用。CAR—T治疗越来越受到人们的关注，尤其在B系来源的淋巴细胞白血病治疗中取得了较好效果。作为固有免疫中重要的效应细胞，自然杀伤（NK）细胞因具有强大的抗肿瘤功能，在肿瘤免疫治疗方面应用前景广阔。NK细胞的CAR修饰潜力也受到了关注，已有靶向多种血液肿瘤的CAR-NK在体外实验和动物模型中取得显著效果。文章就CAR-NK免疫治疗在血液肿瘤中的研究进展进行综述。

Chimeric antigen receptor modified T （CAR-T） cells have been a kind of promising immunotherapeutie strategy for the treatment of malignances, which could target the specific antigen and exert a specific cytotoxie effect by gene modification of T cells. There has been a great stride in B lymphocytic leukemia along with CAR-T therapy. As the essential effector cells of the innate immune system, natural killer （NK） ceils play a critical role in host immunity against cancer and have a wide application prospect in the tumor immunotherapy. The potential of CAR modification in NK cells has also attracted much attention. A lot of remarkable results have been obtained in vitro experiments and animal model of CAR-NK targeting hematologic neoplasms. This paper reviews the progress of CAR-NK immunotherapy in hematological malignancies.